SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it has been included in a recent Gartner report, entitled, Emerging Tech: Tech Innovators for Generative AI NovelDrug Discovery.
SEOUL, South Korea, Aug. 10, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it is collaborating with Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), on early drug discovery research. Under the terms of the agreement, Standigm will use Nashville Bioscience's extensive, de-identified genomic and clinical data to build new, customized AI models for drug discovery. The mission of the collaboration is to accelerate early-stage drug discovery.
SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced that Younsung Choo has been appointed Chief Executive Officer (CEO). As the new CEO of Standigm, Choo will focus primarily on company strategy, planning, R&D and business development.
Standigm, a workflow AI-driven drug discovery company, announced the celebration of its Synthetic Research Center's first year. In the last 12 months, the company has collaborated with outside researchers to create hundreds of novel molecules that help speed drug discovery, and the lab uniquely enables collaboration between chemical and AI researchers
SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the last 12 months, the company has collaborated with outside researchers to create hundreds of novel molecules that help speed drug discovery.
CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe taking place October 24–26, 2022 in Leipzig, Germany. After being delivered digitally over the last two years, the event is expected to bring together over 4,000 executives from biotech, pharma and finance companies to engage in 27,000+ one-to-one meetings.